Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01737619 · ClinicalTrials.gov registry record · NA
PET/CT and Lymph Node Mapping in Finding Lymph Node Metastasis in Patients With High-Risk Endometrial Cancer
A NA study of Endometrial Serous Adenocarcinoma and Endometrial Clear Cell Adenocarcinoma, sponsored by M.D. Anderson Cancer Center.
- Active
- Registry status
- NA
- Development phase
- 101
- Enrollment target
- 7
- Study locations
NCT01737619: Active NA study of Endometrial Serous Adenocarcinoma and Endometrial Clear Cell Adenocarcinoma, sponsored by M.D. Anderson Cancer Center.
NCT01737619 is a NA study of Endometrial Serous Adenocarcinoma and Endometrial Clear Cell Adenocarcinoma that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 101 participants, below the 293-participant average among 12 other Endometrial Serous Adenocarcinoma trials with a reported enrollment target (66% lower). The trial reports 7 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01737619, a NA study of Endometrial Serous Adenocarcinoma and Endometrial Clear Cell Adenocarcinoma, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 101 participants
- Enrollment target
- 7
- Study locations
Study Summary
This clinical trial studies positron emission tomography (PET)/computed tomography (CT) and lymph node mapping in finding lymph node metastasis in patients with endometrial cancer that is at high risk of spreading. A PET/CT scan is a procedure that combines the pictures from a PET scan and a CT scan, which are taken at the same time from the same machine. The combined scans give more detailed pictures of areas inside the body than either scan gives by itself. Lymph node mapping uses a radioactive dye, called indocyanine green solution, to identify lymph nodes that may contain cancer cells. PET/CT and sentinel lymph node mapping may be better ways than surgery to identify cancer in the lymph nodes.
Conditions Studied
Interventions
- PROCEDURE Computed Tomography
- OTHER Laboratory Biomarker Analysis
- PROCEDURE Lymphadenectomy
- DRUG Indocyanine Green Solution
- PROCEDURE Lymph Node Mapping
Study Locations (7)
Texas
- Lyndon Baines Johnson General Hospital - Houston
- M D Anderson Cancer Center - Houston
- The Woman's Hospital of Texas - Houston
- MD Anderson Regional Care Center-Katy - Houston
- MD Anderson Regional Care Center-Bay Area - Nassau Bay
- MD Anderson Regional Care Center-Sugar Land - Sugar Land
- MD Anderson Regional Care Center-The Woodlands - The Woodlands
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 101 participants |
| Start Date | 2013-04-03 |
| Est. Completion | 2025-12-31 |
| Phase | NA |
What the registry record for NCT01737619 still lists
NCT01737619 is an interventional study that assigns participants to a tested intervention. The registered 101 participants enrollment target is mid-sized for trials with a published cap, below the 293-participant average among 12 other Endometrial Serous Adenocarcinoma trials with a reported enrollment target (66% lower).
The record links to 5 conditions, with Endometrial Serous Adenocarcinoma appearing as the primary indexed condition, and to 5 interventions - of which Computed Tomography is the first listed.
NCT01737619 lists 7 locations in 1 state (Texas).
Frequently Asked Questions
What is clinical trial NCT01737619 about?
NCT01737619 is a clinical study titled "PET/CT and Lymph Node Mapping in Finding Lymph Node Metastasis in Patients With High-Risk Endometrial Cancer". This clinical trial studies positron emission tomography (PET)/computed tomography (CT) and lymph node mapping in finding lymph node metastasis in patients with endometrial cancer that is at high risk of spreading. A PET/CT scan is a procedure that combines the pictures from a PET scan and a CT scan...
What is the current status of trial NCT01737619?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 101 participants. The study started on 2013-04-03. Estimated completion is 2025-12-31.
What conditions does trial NCT01737619 study?
This clinical trial studies the following conditions: Endometrial Serous Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Mixed Adenocarcinoma, Grade 3 Endometrial Endometrioid Adenocarcinoma, Malignant Mixed Mesodermal (Mullerian) Tumor.
What interventions are being tested in trial NCT01737619?
The interventions under investigation include: Computed Tomography (PROCEDURE), Laboratory Biomarker Analysis (OTHER), Lymphadenectomy (PROCEDURE), Indocyanine Green Solution (DRUG), Lymph Node Mapping (PROCEDURE).
Who is sponsoring clinical trial NCT01737619?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01737619 being conducted?
This trial has 7 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Endometrial Serous Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01737619's enrollment target sits among peer trials
101 8th of 12 higher than 5 of 12 other Endometrial Serous Adenocarcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Endometrial Serous Adenocarcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
RECRUITING · Phase 3
-
Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer
RECRUITING · Phase 3
-
Determine the Utility of Liquid Biopsies and Tumor Molecular Profiling in Predicting Recurrence in Endometrial Cancers
RECRUITING
-
Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone
ACTIVE NOT RECRUITING · Phase 2
-
Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer
ACTIVE NOT RECRUITING · Phase 3
-
TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04033497 · 101 participants · NA
Treatment Response Assessment Maps to Delineate Necrosis From Tumor After Stereotactic Radiation in Brain Metastases
- NCT05111574 · 101 participants · Phase 2
Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery
- NCT05984680 · 101 participants
COPD Care Pathway Among Patients With Cancer
- NCT06266299 · 101 participants · Phase 1
A Study of KK2269 in Adult Participants With Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI